No Data
No Data
BeiGene to Award Shares Worth $15 Million to 11 Directors
BeiGene (HKG:6160, SHA:688235) will grant restricted share units (RSUs) and performance share units (PSUs) to 11 directors under the firm's 2016 Share Option and Incentive Plan, according to a Tuesday
Hong Kong Stock Concept Tracking | Beijing introduces policies to support the high-quality development of innovative pharmaceuticals, institutions are optimistic about the rise of the domestic innovative drug industry chain (with concept stocks)
Various departments including the Beijing Municipal Medical Security Administration and the Beijing Drug Administration issued a number of measures to support the high-quality development of innovative medicines in Beijing
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
BeiGene (06160.HK): Proposal to grant restricted share units and performance share units to directors
Gelonghui, April 16, 丨 BeiGene (06160.HK) issued an announcement. The board of directors has decided to grant restricted share units and performance share units in accordance with the 2016 plan proposal, subject to acceptance and independent shareholders' approval at the annual shareholders' meeting; granting Mr. Ou a restricted share unit with a fair value of US$6 million on the grant date; granting Mr. Ou a performance share unit with a fair value of US$6 million on the grant date; and awarding restricted share units with a fair value of US$1,333,300 on the grant date; and granting independent non-executive directors (Namely Brandico
BeiGene(BGNE.US) Officer Sells US$7.48 Million in Common Stock
$BeiGene(BGNE.US)$ Officer OYLER JOHN sold 50,000 shares of common stock on Apr 9, 10, 11, 2024 at an average price of $149.5005 for a total value of $7.48 million.Source: Announcement What is stateme
Market Chatter: Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
Western pharmaceutical companies Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX) and BeiGene (BGNE) are seeking alternative suppliers amid the proposed Biosecure Act in the US that would forbid US firm
No Data
SpyderCall : Very valuable info as usual. Thanks for the hard work.
shintaka1168 : こんな情報を配信してくれるなんて、おどろきました。これからもチェックしようと思います